



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/586,288

07/13/2006

Cigdem F. Dogulu

4239-66342-08

2429

36218 7590 03/17/2008

KLARQUIST SPARKMAN, LLP  
121 S.W. SALMON STREET  
SUITE #1600  
PORTLAND, OR 97204-2988

EXAMINER

GREENE, JAIME M

ART UNIT

PAPER NUMBER

1634

MAIL DATE

DELIVERY MODE

03/17/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/586,288	<b>Applicant(s)</b> DOGULU ET AL.	
	<b>Examiner</b> JAIME M. GREENE	<b>Art Unit</b> 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on 16 November 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,8,10-25 and 29 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,8,10-25 and 29 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>7/06</u> .  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

1. This action is in response to papers filed 11/16/07. Claims 1, 8, 10-25 and 29 are pending and are under examination on the merits.

#### ***Information Disclosure Statement***

2. The information disclosure statement (IDS) was filed on 7/13/06. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. It should be noted that one reference was not in English and therefore was crossed out, indicating that it was not considered.

#### ***Election/Restrictions***

3. Applicant's election of Group I (claims 1-25 and 29) and the 143 mutations or polymorphisms in Table 1 in the reply filed on 11/16/07 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

4. It is noted that claims 1 and dependent claims are not commensurate in scope with the election of the 143 mutations or polymorphisms in Table 1. Therefore, the claim 1 and dependent claims are being examined as far as they read on "determining whether the subject has the 143 mutations or polymorphisms in at least 143 of the mutations or polymorphisms listed in Table 1...wherein the presence of all 143 mutations or polymorphisms indicates that the subject has a genetic predisposition to VT" and all other scopes have been withdrawn from consideration as being drawn to a

nonelected invention. In addition, independent claims 22 and 29 are also being examined as far as they read on (claim 22) determining if the amplification products comprise all 143 mutations or polymorphisms, wherein the presence of all 143 mutations or polymorphisms indicates that the subject has a genetic predisposition to VT and (claim 29) the amplification products comprise all 143 polymorphisms.

### ***Claim Objections***

5. Claims 23 and dependent claims 24-25 are objected to because they do not properly depend from claim 1. As stated in MPEP 608.01(n), "The test as to whether a claim is a proper dependent claim is that it shall include every limitation of the claim from which it depends (35 U.S.C. 112, fourth paragraph) or in other words that it shall not conceivably be infringed by anything which would not also infringe the basic claim. On the other hand, if claim 1 recites a method of making a specified product, a claim to the product set forth in claim 1 would not be a proper dependent claim since it is conceivable that the product claim can be infringed without infringing the base method claim if the product can be made by a method other than that recited in the base method claim." In the present situation, claims 23-25 depend from the method of detecting a mutation or polymorphism in a VT-related molecule according to the method of claim 1, however, claim 1 is directed to a method for detecting a genetic predisposition to venous thrombosis in a subject. Thereby, claims 23-25 do not require all of the limitations of claim 1.

6. Claim 29 is objected to because it does not properly depend from claim 13. As stated in MPEP 608.01(n), "The test as to whether a claim is a proper dependent claim

Art Unit: 1634

is that it shall include every limitation of the claim from which it depends (35 U.S.C. 112, fourth paragraph) or in other words that it shall not conceivably be infringed by anything which would not also infringe the basic claim. On the other hand, if claim 1 recites a method of making a specified product, a claim to the product set forth in claim 1 would not be a proper dependent claim since it is conceivable that the product claim can be infringed without infringing the base method claim if the product can be made by a method other than that recited in the base method claim.” In the present situation, the method of claim 29 does not include all of the limitations of claim 13, since claim 29 requires only the array of claim 13, but claim 13 is drawn to method that includes the use of the array. Appropriate correction is required.

***Claim Rejections - 35 USC § 112***

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 1, 8, 10-25 and 29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

9. Claims 1 and 22 recite “at least the 143 mutations or polymorphisms listed in Table 1”. This renders the claims indefinite because Table 1 only contains 143 mutations or polymorphisms and it is unclear to which additional mutations or polymorphisms the claim is referring. Appropriate correction is required.

10. Claims 8, 10-21 and 23-25 depend from claim 1 and are indefinite for the reasons applied to claim 1.

***Claim Rejections - 35 USC § 112***

11. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

12. Claims 1, 8, 10-25 and 29 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The test of enablement is whether one skilled in the art could make and use the claimed invention from the disclosures in the application coupled with information known in the art without undue experimentation (*United States v. Teletronics Inc*, 8 USPQ2d 1217 (Fed Cir. 1988)). Whether undue experimentation is needed is not based on a single factor, but rather a conclusion reached by weighing many factors (See *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Inter. 1986)) and *In re Wands* 8 USPQ2d 1400 (Fed. Cir. 1988)).

The breadth of the claims and nature of the invention

Claims 1, 8, 10-21, 23-25 and 29 are broadly drawn to a method of detecting genetic predisposition to venous thrombosis (VT) in any subject, comprising: determining whether the any subject has 143 mutations or polymorphisms in at least 143 of the mutations or polymorphisms listed in Table 1, wherein the mutations or polymorphisms are present in at least eight VT-related molecules comprising

Art Unit: 1634

antithrombin III (AT III), protein C, protein S, fibrinogen, factor V (FV), prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR) and angiotensin 1-converting enzyme (ACE), and wherein the presence of the 143 mutations or polymorphisms indicates that the subject has a genetic predisposition for venous thrombosis.

Claim 8 further requires that the method provide a probability of developing VT of at least 98% in Caucasians, at least 85% in Asians, and at least 87% in Africans.

Claim 22 is broadly drawn to a method of detecting genetic predisposition to VT in any subject, comprising: applying amplification products to an array, wherein the array comprises oligonucleotide probes capable of detecting at least the 143 mutations or polymorphisms listed in Table 1, and wherein the amplification products comprise nucleic acid sequences from AT III, protein C, protein S, fibrinogen, factor V, factor II, MTHFR and ACE, obtained from the subject; incubating the amplification products with the array for a time sufficient to allow hybridization between the amplification products and oligonucleotide probes, thereby forming amplification products: oligonucleotide probe complexes; and analyzing the amplification products: oligonucleotide probe complexes to determine if the amplification products comprise the 143 mutations or polymorphisms in the AT III, protein C, protein S, fibrinogen, factor V, factor II, MTHFR or ACE sequences, wherein the presence of the 143 mutations or polymorphisms indicates that the subject has a genetic predisposition for VT.

Claim 29 is broadly drawn to a method of detecting a genetic predisposition to venous thrombosis (VT) in a subject, comprising: applying amplification products to the array of claim 13, wherein the amplification products comprise amplified nucleic acids

Art Unit: 1634

obtained from the subject, wherein the nucleic acids comprise coding or non-coding sequences from AT III, protein C, protein S, fibrinogen, factor V, factor II, MTHFR and ACE. incubating the amplification products with the array for a time sufficient to allow hybridization between the amplification products and oligonucleotide probes, thereby forming amplification products: oligonucleotide probe complexes; and analyzing the amplification products: oligonucleotide probe complexes to determine if the amplification products comprise the 143 mutations or polymorphisms in the AT III, protein C, protein S, fibrinogen, factor V, factor II, MTHFR, or ACE genes, wherein the presence of the 143 mutations or polymorphisms indicates that the subject has a genetic predisposition for VT.

Since the specification defines the term subject as living multi-cellular vertebrate organisms, a category that includes human and non-human mammals (such as veterinary subjects), the methods involve detecting predisposition to VT in any organism.

Since the claims do not specify the ethnicity of the patients examined, the claims broadly encompass detecting predisposition to VT in human subjects of any ethnicity, including Caucasians, African Americans, Koreans, Chinese, etc. Also, claim 8 requires probability of developing VT of at least 98% in Caucasians, at least 85% in Asians, and at least 87% in Africans, however, independent claim 1 does not provide any steps for determining a probability and therefore it is unpredictable to what probability the claim is referring and therefore also unpredictable to achieve said probabilities by the claimed method.



Guidance in the Specification and Working Examples

The specification characterizes 143 mutations and polymorphisms as being associated with venous thrombosis (pp 70-71, table 1). However, in example 1, the specification only teaches analyzing 10 of the VT associated susceptibility alleles for calculations of logistic regression and likelihood ratios for predicting the probability of developing VT, and the specification teaches that the data used for the calculations were derived from previously reported studies (pg 71, lines 5-18 to pg 73). In Table 3 (pg 75), the specification teaches the likelihood ratios and probabilities for developing VT for each polymorphism assesses. However, the table does not teach which Antithrombin III polymorphism was analyzed to yield the data in the table. In addition, many of the likelihood ratios were only calculated for certain ethnic populations: for example, the fibrinogen Thr312A1a polymorphism was only analyzed in Caucasian populations. Therefore, it is unclear from the data in the specification how to use each of the 10 analyzed polymorphisms/mutations to determine genetic predisposition to venous thrombosis in any population, and thereby is unpredictable to use any of those polymorphisms/mutations to determine genetic predisposition to venous thrombosis in any population. Further, since there is no data in the specification for the remaining 133 polymorphisms it is unpredictable to use any of the 133 polymorphisms/mutations to determine genetic predisposition to venous thrombosis in any population.

Finally, the specification states that concurrent screening of the 8 genes results in a 99.7% probability of developing VT in Caucasian populations, an 85.1% probability in Asian populations and an 88.7% probability in African populations (pp 75-76).

Art Unit: 1634

However, it is unclear how these numbers were calculated for each population, since only 3 of the 8 polymorphisms/mutations were studied in all 3 populations. Further, the specification states that, e.g. the FV Cambridge G to C mutation at position 1091 has only been described in Caucasian populations (pg 51). Therefore, based on the lack of descriptive data in the specification, along with statements that certain mutations are only known in Caucasian populations, it is unpredictable to use the combination of 8 polymorphisms/mutations to predict genetic predisposition to venous thrombosis in any ethnic population.

The specification does not teach performing studies in non-human organisms. The specification does not teach more than 143 mutations or polymorphisms in Table 1. The specification does not teach studying more than the eight VT-related gene identified in Table 1.

The unpredictability of the art, the state of the prior art, level of skill in the art

While the state of the art and level of skill in the art with regard to correlating polymorphisms or mutations with disease state is high, the level of unpredictability in associating any polymorphism or mutation with a particular disease state is even higher. The level of unpredictability is demonstrated by the prior art, the post filing art, and the instant specification.

Nagaraja (Nagaraja, et al. Journal of Clinical Neuroscience, July 2007; 14(7):635-638) teaches studying the prevalence of the prothrombin G20210A variant in south Indian women and examine its association with cerebral veno-sinus thrombosis (CVT)—a type of venous thrombosis— occurring during puerperium in these women.

Art Unit: 1634

Nagaraja teaches that studies evaluating the prothrombin variant in CVT report frequencies varying from 0 to 50% and that differences in the frequencies reported in those studies might be explained by ethnic differences (pg 637, col 1). Nagaraja also teaches an absence of the G20210A variant in women their study and suggest that the result is due to absence of the G20210A variant in the general Indian population (pg 637, col 1). Therefore, based on the data described by Nagaraja, it is unpredictable to use the prothrombin G20210A variant to predict predisposition to VT in any Asian population, and further, based on the summary of previous studies by Nagaraja it is also unpredictable to use the G20210A variant to predict predisposition to VT in any human population.

Bezemer (Bezemer, et al. Arch Intern Med. 2007 Mar 12;167(5):497-501).

Bezemer teaches a single large study on the association between MTHFR 677C→T polymorphism and venous thrombosis that included 4375 patients with a first venous thrombotic event, either deep vein thrombosis of the leg or pulmonary embolism, and 4856 control subjects from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA Study) (pg 498, col 1). Bezemer teaches that the patients were all Dutch speakers and that the study was performed in the Netherlands. Bezemer teaches that no evidence was found for an association between MTHFR 677C→T and the risk of venous thrombosis. Therefore, based on the results of this study, it is unpredictable to use the MTHFR 677C→T polymorphism to predict genetic predisposition to venous thrombosis in Dutch patients and thereby in any population.

Halushka (Halushka, et al. Nature Genetics, 1999; 22:239-247) teaches

Art Unit: 1634

assessing the age or ancestral state of human SNP alleles by obtaining the corresponding orthologous sequence from the closely related great apes (page 244, column 1, paragraph 2). Halushka teaches that although there was a high degree of sequence identity between great ape and human samples (page 244, column 2, paragraph 1), the average nucleotide divergence between human and chimpanzee, gorilla and orangutan was 0.010, 0.012 and 0.021, respectively, and that and that these values are more than ten times greater than the within-population human diversity (page 244, column 2, paragraph 1). Halushka teaches that the data suggest that 95% of population-specific SNPs arose in the human lineage after population differentiation and that the common allele [between human and ape] is the likely ancestral state.

Regarding using polymorphisms to make predictions, the art teaches genetic variations and associations are often irreproducible. Hirschhorn (Hirschhorn et al. Genetics in Medicine. Vol. 4, No. 2, pages 45-61, March 2002) teaches that most reported associations are not robust. Of the 166 associations studied three or more times, only 6 have been consistently replicated. Hirschhorn suggests a number of reasons for the irreproducibility of studies, suggesting population stratification, linkage disequilibrium, gene-gene or gene-environment interactions, and weak genetic effects and lack of power are possible factors that lead to such irreproducibility. Hirschhorn et al. caution that the current irreproducibility of most association studies should raise a cautionary alarm when considering their use as diagnostics and prognostics (p. 60, Col. 2). Thus, Hirschhorn cautions in drawing conclusions from a single report of an association between a genetic variant and disease susceptibility.

Ioannidis (Ioannidis. Nature Genetics, Vol. 29, pages 306-309, November 2001) teaches that the results of the first study correlate only modestly with subsequent research on the same association (abstract). Ioannidis teaches that both bias and genuine population diversity might explain why early association studies tend to overestimate the disease protection or predisposition conferred by a genetic polymorphism (abstract). Therefore, it is unpredictable to use genetic associations for diagnostic purposes.

Kroese et al. (Kroese et al., Genetics in Medicine, vol 6 (2004), p. 475-480) teach genetic tests are heterogeneous in nature and the exact characteristics of a particular genetic test to be evaluated must be tightly defined. Kroese et al. teach that a particular genetic condition may be caused by more than one gene and these variations may be due to deletions and insertions not detected by routine sequence methods (see page 476, 2nd column, last paragraph). Kroese et al. teach that genetic test is shorthand to describe a test to detect a particular genetic variant for a particular disease in a particular population and for a particular purpose and that it should not be assumed that once the characteristics of a genetic test are evaluated for one of these reasons that the evaluation will hold or be useful for other purposes and all measures of the test performance should be presented with their 95% confidence intervals (see page 477, 1st column, 1st and 2nd full paragraph). Kroese et al. teach that the limitations of our genetic knowledge and technical abilities means that for the moment there are likely to be gaps in the information needed to complete a thorough evaluation of many genetic tests (see page 479, 2nd column, last paragraph).

Quantity of Experimentation

Claims 1, 8, 10-21, 23-25 and 29 are broadly drawn to a method of detecting genetic predisposition to venous thrombosis (VT) in any subject, comprising: determining whether the any subject has 143 mutations or polymorphisms in at least 143 of the mutations or polymorphisms listed in Table 1, wherein the mutations or polymorphisms are present in at least eight VT-related molecules comprising antithrombin III (AT III), protein C, protein S, fibrinogen, factor V (FV), prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR) and angiotensin 1-converting enzyme (ACE), and wherein the presence of the 143 mutations or polymorphisms indicates that the subject has a genetic predisposition for venous thrombosis. The specification only teaches studies to identify correlations between antithrombin III (AT III), protein C, protein S, fibrinogen, factor V (FV), prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR) and angiotensin 1-converting enzyme (ACE) and VT, and the specification does not teach studying additional genes. Therefore, the skilled artisan would be required to perform a large study to identify other genes that contain mutations/polymorphisms that may be correlated with VT predisposition and to study whether or not there is such a correlation. This would require undue and unpredictable experimentation with no expectation of success.

Claims 1, 8, 10-21, 23-25 and 29 are broadly drawn to a method of detecting genetic predisposition to venous thrombosis (VT) in any subject, comprising: determining whether the any subject has 143 mutations or polymorphisms in at least 143 of the mutations or polymorphisms listed in Table 1. Claim 22 is broadly drawn to a

Art Unit: 1634

method of detecting genetic predisposition to VT in any subject, comprising: applying amplification products to an array, wherein the array comprises oligonucleotide probes capable of detecting at least the 143 mutations or polymorphisms listed in Table 1. The specification only teaches 143 mutations or polymorphisms in Table 1. Therefore, it is unclear to which other polymorphisms the claim is drawn. Therefore the skilled artisan would be required to perform a large study to identify other polymorphisms and to identify which of those polymorphisms can be associated with predisposition to VT. This would require undue and unpredictable experimentation with no expectation of success.

Claims 1, 8, 10-25 and 29 are broadly drawn to methods of detecting genetic predisposition to venous thrombosis (VT) in any subject. The specification only teaches studies in humans. Halushka teaches assessing the age or ancestral state of human SNP alleles by obtaining the corresponding orthologous sequence from the closely related great apes. Halushka teaches that the data suggest that 95% of population-specific SNPs arose in the human lineage after population differentiation and that the common allele [between human and ape] is the likely ancestral state. This indicates that SNPs identified in the human population do not necessarily have a corresponding SNP in other organisms. Therefore, the skilled artisan would be required to identify if there are corresponding SNPs in non-human organisms and then to perform a large study to determine if those SNPs could be used to predict genetic predisposition to VT in those non-human organisms. This would require undue and unpredictable experimentation with no expectation of success.

Claims 1, 8, 10-21, 23-25 and 29 are broadly drawn to a method of detecting genetic predisposition to venous thrombosis (VT) in any subject, comprising: determining whether the any subject has 143 mutations or polymorphisms in at least 143 of the mutations or polymorphisms listed in Table 1, wherein the mutations or polymorphisms are present in at least eight VT-related molecules comprising antithrombin III (AT III), protein C, protein S, fibrinogen, factor V (FV), prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR) and angiotensin 1-converting enzyme (ACE), and wherein the presence of the 143 mutations or polymorphisms indicates that the subject has a genetic predisposition for venous thrombosis. Claim 22 is broadly drawn to a method of detecting genetic predisposition to VT in any subject, comprising: applying amplification products to an array, wherein the array comprises oligonucleotide probes capable of detecting at least the 143 mutations or polymorphisms listed in Table 1, and wherein the amplification products comprise nucleic acid sequences from AT III, protein C, protein S, fibrinogen, factor V, factor II, MTHFR and ACE, obtained from the subject; incubating the amplification products with the array for a time sufficient to allow hybridization between the amplification products and oligonucleotide probes, thereby forming amplification products: oligonucleotide probe complexes; and analyzing the amplification products: oligonucleotide probe complexes to determine if the amplification products comprise the 143 mutations or polymorphisms in the AT III, protein C, protein S, fibrinogen, factor V, factor II, MTHFR or ACE sequences, wherein the presence of the 143 mutations or polymorphisms indicates that the subject has a genetic predisposition for VT. The specification



Art Unit: 1634

teaches studying 10 of the 143 polymorphisms and Table 3 indicates that 7 of the polymorphisms were not studied in all ethnic populations. Also, while the specification indicates in Table 1 that, for example, a Caucasian patient with the MTHFR 677C→T SNP has a 0.16% probability of developing VT, Bezemer teaches in a study of Dutch patients that there is no association between the MTHFR 677C→T SNP and VT. Since many Dutch people are also Caucasian, the data from Bezemer and in the specification conflict with regard to the use of MTHFR C677T as predictive of VT, and therefore it is unpredictable to use MTHFR C677T as a means of predicting genetic predisposition to VT in Caucasian populations. Also, while the specification teaches that the Prothrombin G20210A SNP when present in a Caucasian patient indicates a 0.2% probability of developing VT, Nagaraja teaches that studies evaluating the prothrombin variant in CVT report frequencies varying from 0 to 50% and Nagaraja teaches an absence of the G20210A variant in women their study and suggests that the result is due to absence of the G20210A variant in the general Indian population. Therefore, due to conflicting data from the combination of results from Nagaraja, other reported studies, and the data in the specification, it is unpredictable to use of the G20210A variant to predict genetic predisposition to VT. Finally, Hirschhorn, Ioannidis and Kroese teach that the association between SNPs and disease is often unpredictable due to the number of variable associated with performing such studies, variables including population diversity, linkage disequilibrium and gene-environment interactions. Therefore, the skilled artisan would be required to perform a very large study to determine if the combination of 143 polymorphisms can be used in any ethnic population to predict

genetic predisposition to VT. This would require undue and unpredictable experimentation with no expectation of success.

Claim 8 requires that the method of claim 1 provide a probability of developing VT of at least 98% in Caucasians, at least 85% in Asians, and at least 87% in Africans. The specification teaches that concurrent screening of the 8 genes results in a probability of VT of 99.7% in Caucasian, an 85.1% probability in Asians and an 88.7% probability in Africans. However, the data in the table also indicates that only 3 of the 10 SNPs were studied in the three ethnic populations. Therefore it is unclear how the values were calculated for all 8 genes, and since there is no data for the other 133 mutations, it is unclear what the values would be for the combination. In addition, the method does not provide a means of determining the claimed probabilities. Therefore, it is unpredictable to use the combination of 143 SNPs to determine a probability of developing VT of at least 98% in Caucasians, at least 85% in Asians, and at least 87% in Africans, and the skilled artisan would be required to perform a large study to identify a formula to use that would result in all 143 of the SNPs/mutations yielding a probability of developing VT of at least 98% in Caucasians, at least 85% in Asians, and at least 87% in Africans. This would require undue and unpredictable experimentation with no expectation of success.

### Conclusion

Given the lack of data from all organisms, the conflicts between the art and specification on polymorphisms that are associated with VT, and the lack of guidance in the claims and specification for how to perform the claimed methods, methods of

detecting genetic predisposition to venous thrombosis (VT) are replete with unpredictable experimentation that is considered undue.

Thus given the broad claims in an art whose nature is unpredictable, the unpredictability of that art, the large quantity of research required to define these unpredictable variables, the lack of guidance provided in the specification, and the negative teachings in the prior art balanced only against the high skill level in the art, it is the position of the examiner that it would require undue experimentation for one of skill in the art to perform the methods of the claims as broadly written.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAIME M. GREENE whose telephone number is (571)270-3052. The examiner can normally be reached on Monday-Thursday, 7:30am-5:00pm, ALT. Friday, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1634

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jaime M. Greene 2/21/08

/Carla Myers/  
Primary Examiner, Art Unit 1634